SCHEMBL752570

SCHEMBL752570

Cc1nc(N)cc(-c2c(Nc3ccc(C(N)=O)cc3)nc3ccccn23)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 12/20 0.61
MTOR P42345 12/20 0.61
PIK3CB P42338 1/20 0.43
CDK2 P24941 2/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
PIM1 P11309 1/20 0.40
RPS6KB1 P23443 1/20 0.40
FLT4 P35916 1/20 0.40
FLT3 P36888 1/20 0.40
MAPK8 P45983 1/20 0.40
MAPK9 P45984 1/20 0.40
CSNK1D P48730 1/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
CSNK2A1 P68400 1/20 0.40
DYRK1A Q13627 1/20 0.40
TAOK1 Q7L7X3 1/20 0.40
PIM3 Q86V86 1/20 0.40
PRKD2 Q9BZL6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL750438 0.89 PIK3CA (0.57) PIK3CAMTORCDK2ALDH1A1LMNA
SCHEMBL751862 0.88 PIK3CA (0.56) PIK3CAMTORPIK3CBKDM4EALDH1A1
SCHEMBL2790005 0.87 PIK3CA (0.62) PIK3CAMTORPIK3CBCDK2ALDH1A1
SCHEMBL11028397 0.86 PIK3CA (0.59) PIK3CAMTORPIK3CBCDK2LMNA
SCHEMBL2771022 0.85 PIK3CA (0.62) PIK3CAMTORPIK3CBCDK2KMT2A
SCHEMBL16161626 0.84 PIK3CA (0.56) PIK3CAMTORPIK3CBCDK2PRKD3
SCHEMBL2775861 0.84 PIK3CA (0.56) PIK3CAMTORPIK3CBCDK2KDM4E
SCHEMBL752836 0.83 PIK3CA (0.57) PIK3CAMTORPIK3CBCSNK2A1KDM4E
SCHEMBL758618 0.83 PIK3CA (0.51) PIK3CAMTORCDK2ALDH1A1LMNA
SCHEMBL11032907 0.82 PIK3CA (0.54) PIK3CAMTORCDK2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP claimed
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US claimed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP claimed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO claimed
EP-2430013-B1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC (US) 2014-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD PIK3CA 1/4885MTOR 21/4885PIK3CB 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.